Mark J Mitton-Fry

This inventor holds 8 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Pfizer Corporation, Zoetis Services LLC, The Ohio State University. Active years: 2012-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark J Mitton-Fry. Retrieved from https://idiyas.com/inventor/mark-j-mitton-fry

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 4.4

ph-index = 3

Forward Citations = 37(Granted Patents)

Location History:

Clinton, CT (US) (2012 - 2016)
Granville, OH (US) (2015 - 2022)

Company Filing History:

The Ohio State University

Years Active: 2012-2022

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11352349 - Type II topoisomerase inhibitors and methods of making and using thereof (2022-06-07),

2. 9549929 - Pyrrolo[2,3-D]pyrimidine derivatives (2017-01-24),

3. 9545405 - Pyrrolo[2,3-D]pyrimidine derivatives (2017-01-17),

4. 9271981 - Pyrrolo[2,3-D]pyrimidine compounds (2016-03-01),

5. 9161939 - Pyrrolo[2,3-d]pyrimidine compounds (2015-10-20),

6. 9035074 - Pyrrolo[2,3-D]pyrimidine derivatives (2015-05-19),

7. 8987283 - Pyrrolo[2,3-D]pyrimidine compounds (2015-03-24),

8. 8133899 - [object Object] (2012-03-13),

Title: The Innovations of Mark J Mitton-Fry

Introduction

Mark J Mitton-Fry is a notable inventor based in Clinton, CT, with a significant contribution to the field of pharmaceuticals. He holds a total of 8 patents, showcasing his innovative approach to developing new treatments and compounds. His work primarily focuses on inhibitors that target specific biological processes, which can lead to advancements in medical therapies.

Latest Patents

Among his latest patents are the Type II topoisomerase inhibitors and methods of making and using them. These patents disclose Type II Topoisomerase Inhibitors, their analogs, and pharmaceutical compositions. The methods described include using these compounds to treat infections caused by pathogens such as MRSA and MDR. Another significant patent involves pyrrolo[2,3-D]pyrimidine derivatives, which are recognized for their use as Janus Kinase (JAK) inhibitors and the pharmaceutical compositions that contain them.

Career Highlights

Mark has had a distinguished career, working with prominent companies such as Pfizer Corporation and Zoetis Services LLC. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to the advancement of pharmaceutical science.

Collaborations

Throughout his career, Mark has collaborated with talented individuals, including Andrea Joy Gonzales and Pamela J Berlinski. These collaborations have likely enriched his work and led to the development of impactful inventions.

Conclusion

Mark J Mitton-Fry's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for new treatments and innovations in medicine.

Profile summary based on public USPTO records.